Lipomics Technologies, Inc., a company specializing in the comprehensive and quantitative profiling of lipid metabolites, today announced the availability of a new acylcarnitine profiling platform that will help accelerate the pace of drug discovery and development for a wide range of critical diseases and metabolic conditions.
